Rein Therapeutics, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Operating Expenses
Income Breakdown
Revenue
$0
R&D
$11M
D&A
$1K
Operating Income
$-51M
EBITDA
$-51M
Interest Expense
—
Tax Provision
$-712K
Net Income
$-50M
Deferred Tax Assets
$2M
Deferred Tax Liabilities
$1M
DTA Valuation Allowance
$42M
Tax Credit Carryforwards
—
NOL Carryforwards
$29M
ETR (Continuing Operations)
1.4%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-1.2%
ETR Foreign Differential (pp)
0.0%
Operating Lease Cost
—
Income YoY Variation
22.2%